Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR2 | P41597 | 4/20 | 0.59 |
| ▸ | DAO | P14920 | 1/20 | 0.54 |
| ▸ | MCL1 | Q07820 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | TSHR | P16473 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | PLA2G10 | O15496 | 2/20 | 0.45 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.42 |
| ▸ | IDO1 | P14902 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | LDHA | P00338 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1672526 | 0.84 | MTNR1A (0.48) | CCR2DAOMCL1ALDH1A1MEN1 | |
| SCHEMBL13802195 | 0.82 | NOD2 (0.62) | CCR2ALDH1A1TSHRPOLBMEN1 | |
| SCHEMBL29780995 | 0.80 | DAO (0.65) | CCR2DAOMCL1ALDH1A1TSHR | |
| SCHEMBL3638561 | 0.80 | DAO (0.65) | CCR2DAOMCL1ALDH1A1TSHR | |
| SCHEMBL3831363 | 0.78 | KDM1A (0.56) | CCR2DAOMCL1ALDH1A1TSHR | |
| SCHEMBL4222282 | 0.77 | MCL1 (0.64) | CCR2DAOMCL1ALDH1A1TSHR | |
| SCHEMBL6882643 | 0.76 | MCL1 (0.50) | CCR2DAOMCL1ALDH1A1TSHR | |
| SCHEMBL9514581 | 0.76 | DAO (0.59) | CCR2DAOMCL1ALDH1A1TSHR | |
| SCHEMBL14398966 | 0.74 | MCL1 (0.60) | CCR2DAOMCL1ALDH1A1TSHR | |
| SCHEMBL5378162 | 0.74 | CCR2 (1.00) | CCR2DAOMCL1ALDH1A1CYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | MYRIAD GENETICS, INCORPORATED (US) | 2009-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090155903-A1 | PHARMACEUTICAL COMPOSITION AND METHOD | APP, PSEN2, PSEN1 | CCR2 1386/4885DAO 4273/4885MCL1 4753/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.